Search
Patexia Research
Case number 1:23-cv-00101

Novo Nordisk Inc. et al v. Mylan Pharmaceuticals Inc. > Documents

Date Field Doc. No.Description (Pages)
Jun 18, 2024 164 NOTICE OF SERVICE of (1) Defendants Supplemental Objections and Responses to Plaintiffs First Set of Interrogatories (Nos. 1-9), (2) Defendants Third Set of Request for Production to Plaintiffs (Nos. 45-50), and (3) Mylan Pharmaceuticals Inc.s Objections and Responses to Plaintiffs Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 06/18/2024) (2)
Jun 18, 2024 165 REDACTED VERSION of 161 Opening Brief in Support, by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 06/18/2024) (28)
Jun 18, 2024 166 REDACTED VERSION of 162 Declaration by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 06/18/2024) (30)
Jun 17, 2024 163 NOTICE OF SERVICE of Novo Nordisk's Opening Claim Construction Brief Regarding U.S. Patent No. 11,752,198 - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 06/17/2024) (4)
Jun 11, 2024 160 MOTION for Judgment on the Pleadings Pursuant to FRCP 12(C) Regarding U.S. Patent No. 9,764,003 - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Attachments: # 1 Certificate of Compliance, # 2 Text of Proposed Order)(Stamoulis, Stamatios) (Entered: 06/11/2024) (0)
Jun 11, 2024 161 [SEALED] OPENING BRIEF in Support re 160 MOTION for Judgment on the Pleadings Pursuant to FRCP 12(C) Regarding U.S. Patent No. 9,764,003 filed by Mylan Pharmaceuticals Inc., Viatris Inc..Answering Brief/Response due date per Local Rules is 6/25/2024. (Stamoulis, Stamatios) (Entered: 06/11/2024) (0)
Jun 11, 2024 162 [SEALED] DECLARATION re 161 Opening Brief in Support, of Aaron E. Schindler by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 06/11/2024) (0)
Jun 6, 2024 157 CLAIM Construction Chart by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Additional attachment(s) added on 6/6/2024: # 1 Exhibit A 198 patent) (kmd). (Entered: 06/06/2024) (0)
Jun 6, 2024 158 MOTION for Claim Construction re 157 Claim Construction Chart - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 06/06/2024) (4)
Jun 6, 2024 159 MOTION for Claim Construction re 157 Claim Construction Chart - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 06/06/2024) (2)
Jun 5, 2024 156 Joint STIPULATION TO EXTEND TIME to file the Joint Claim Construction Chart to June 6, 2024 - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 06/05/2024) (2)
Jun 3, 2024 155 SO ORDERED, re 154 STIPULATION TO EXTEND TIME for the parties to submit a Joint Claim Construction Chart for U.S. Patent No. 11,752,198 to June 5, 2024, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 6/3/2024. (kmd) (Entered: 06/03/2024) (2)
May 31, 2024 154 STIPULATION TO EXTEND TIME for the parties to submit a Joint Claim Construction Chart for U.S. Patent No. 11,752,198 to June 5, 2024 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 05/31/2024) (2)
May 30, 2024 153 SO ORDERED, re 152 STIPULATION TO EXTEND TIME for the deadlines pertaining to the Rule 12(c) motion and briefing to various dates, filed by Novo Nordisk A/S, Novo Nordisk Inc. Reset Briefing Schedule: Opening Brief due 6/11/2024. Answering Brief due 7/9/2024. Reply Brief due 7/23/2024. Signed by Judge Colm F. Connolly on 5/30/2024. (kmd) (Entered: 05/30/2024) (2)
May 28, 2024 151 SO ORDERED, re 148 Stipulation to Extend Claim Construction Deadlines for the '198 Patent, filed by Novo Nordisk A/S, Novo Nordisk Inc. Set/Reset Deadlines for Claim Construction Briefing and Markman Hearing: Claim Construction Opening Brief due by 6/17/2024. Claim Construction Answering Brief due by 7/10/2024. Claim Construction Reply Brief due by 7/29/2024. Claim Construction Surreply Brief due by 8/5/2024. Joint Claim Construction Brief due by 8/7/2024. (See Order for further details.) Signed by Judge Colm F. Connolly on 5/28/2024. (kmd) (Entered: 05/28/2024) (3)
May 28, 2024 152 STIPULATION TO EXTEND TIME for the deadlines pertaining to the Rule 12(c) motion and briefing to various dates - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 05/28/2024) (2)
May 27, 2024 149 MOTION for Pro Hac Vice Appearance of Attorney Aaron E. Schindler - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 05/27/2024) (4)
May 27, 2024 150 Pro Hac Vice Fee - Credit Card Payment received for Aaron E. Schindler. ( re 149 MOTION for Pro Hac Vice Appearance of Attorney Aaron E. Schindler )( Payment of $ 50, receipt number ADEDC-4415729).(Stamoulis, Stamatios) (Entered: 05/27/2024) (0)
May 24, 2024 148 STIPULATION and [Proposed] Order to Extend Claim Construction Deadlines for the '198 Patent - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 05/24/2024) (3)
May 21, 2024 146 SO ORDERED, re 145 STIPULATION TO EXTEND TIME for deadlines pertaining to the Rule 12(c) motion and briefing (D.I. 133) to See Stipulation, filed by Mylan Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 5/21/2024. (kmd) (Entered: 05/21/2024) (2)
May 21, 2024 147 NOTICE OF SERVICE of Plaintiffs' Proposed Constructions and Supporting Intrinsic Evidence for U.S. Patent No. 11,752,198 ("the '198 Patent") - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 05/21/2024) (4)
May 20, 2024 144 NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.s identification of proposed construction and intrinsic evidence for U.S. Patent No. 11,752,198 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 05/20/2024) (2)
May 20, 2024 145 STIPULATION TO EXTEND TIME for deadlines pertaining to the Rule 12(c) motion and briefing (D.I. 133) to See Stipulation - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 05/20/2024) (2)
May 16, 2024 142 STIPULATION and [Proposed] Order to Extend Claim Construction Deadlines for the '198 Patent - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 05/16/2024) (2)
May 16, 2024 143 SO ORDERED, re 142 Stipulation to Extend Claim Construction Deadlines for the '198 Patent, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 5/16/2024. (kmd) (Entered: 05/16/2024) (2)
May 10, 2024 140 NOTICE OF SERVICE of Plaintiffs' Identification of Claim Terms in U.S. Patent No. 11,752,198 for Construction - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 05/10/2024) (4)
May 10, 2024 141 NOTICE OF SERVICE of Redacted Version of Defendants Initial Noninfringement Contentions for U.S. Patent No. 11,752,198 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 05/10/2024) (2)
May 9, 2024 139 NOTICE OF SERVICE of identification of claim terms in U.S. Patent No. 11,752,198 for construction filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 05/09/2024) (2)
May 6, 2024 138 NOTICE OF SERVICE of (1) Plaintiffs' Initial Infringement Contentions Regarding Defendant Mylan Pharmaceuticals Inc. for U.S. Patent No. 11,752,198 and (2) Plaintiffs' Initial Responses to Defendant's Initial Invalidity Contentions Regarding U.S. Patent No. 11,752,198 - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 05/06/2024) (4)
May 2, 2024 137 SO ORDERED, re 136 STIPULATION TO EXTEND TIME Regarding Briefing Schedule for Rule 12(c) Motion to Dates in Stipulation, filed by Viatris Inc., Mylan Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 5/2/2024. (kmd) (Entered: 05/02/2024) (2)
May 1, 2024 136 STIPULATION TO EXTEND TIME Regarding Briefing Schedule for Rule 12(c) Motion to Dates in Stipulation - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 05/01/2024) (2)
Apr 19, 2024 135 NOTICE OF SERVICE of (1) Defendants Initial Noninfringement Contentions for U.S. Patent No. 11,752,198 and (2) Defendants Initial Invalidity Contentions Regarding U.S. Patent No. 11,752,198 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 04/19/2024) (2)
Apr 16, 2024 134 ANSWER to Complaint /Counterclaims of Defendant Mylan Pharmaceuticals Inc. ("Mylan") (D.I. 9, C.A. No. 24-50-CFC) - by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 04/16/2024) (11)
Apr 11, 2024 132 ORDER granting (129) Motion to Consolidate Cases in case 1:23-cv-00101-CFC; granting (12) Motion to Consolidate Cases in case 1:24-cv-00050-CFC. IT IS HEREBY ORDERED that that these actions are consolidated for all purposes, and all papers shall be filed in C.A. No. 23-101-CFC. IT IS FURTHER ORDERED that the Protective Order (C.A. No. 23-101-CFC, D.I. 40) and ESI Order (C.A. No. 23-101- CFC, D.I. 43) shall govern. The Scheduling Order (C.A. No. 23-101-CFC, D.I. 27) shall be modified by the Proposed Consolidated Case Schedule and shall govern. Signed by Judge Colm F. Connolly on 4/10/2024. Associated Cases: 1:23-cv-00101-CFC, 1:24-cv-00050-CFC(nmf) (Entered: 04/11/2024) (2)
Apr 11, 2024 133 CONSOLIDATED CASE SCHEDULING ORDER: Fact Discovery completed by 8/30/2024. Expert Discovery due by 1/20/2025. Joint Claim Construction Brief due by 7/25/2024. A Markman Hearing is set for 9/24/2024 at 09:00 AM in Courtroom 4B before Judge Colm F. Connolly. Proposed Pretrial Order due by 3/11/2025. A Final Pretrial Conference is set for 4/1/2025 at 03:00 PM in Courtroom 4B before Judge Colm F. Connolly. A Bench Trial is set for 4/21/2025 at 08:30 AM in Courtroom 4B before Judge Colm F. Connolly. Signed by Judge Colm F. Connolly on 4/10/2024. (nmf) (Entered: 04/11/2024) (5)
Apr 8, 2024 131 REDACTED VERSION of 114 Transcript,, by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 04/08/2024) (30)
Apr 4, 2024 130 NOTICE OF SERVICE of Novo Nordisk's Preliminary Disclosure of Asserted Claims Regarding U.S. Patent No. 11,752,198 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) (Entered: 04/04/2024) (5)
Mar 28, 2024 127 NOTICE of Intent to Request Redaction by Stamatios Stamoulis re 114 Transcript,,. (Stamoulis, Stamatios) (Entered: 03/28/2024) (2)
Mar 28, 2024 128 Letter to The Honorable Colm F. Connolly from Brian P. Egan regarding motion to consolidate. (Egan, Brian) (Entered: 03/28/2024) (1)
Mar 28, 2024 129 Joint MOTION to Consolidate Cases - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exhibit A)(Egan, Brian) (Entered: 03/28/2024) (0)
Mar 25, 2024 126 MEMORANDUM ORDER re: Claim Construction. Signed by Judge Colm F. Connolly on 3/25/2024. (nmf) (Entered: 03/25/2024) (8)
Mar 22, 2024 124 STIPULATION TO EXTEND TIME for the parties to submit a revised proposed scheduling order to March 28, 2024 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 03/22/2024) (2)
Mar 22, 2024 125 SO ORDERED, re 124 STIPULATION TO EXTEND TIME for the parties to submit a revised proposed scheduling order to March 28, 2024, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 3/22/2024. (kmd) (Entered: 03/22/2024) (2)
Mar 18, 2024 123 NOTICE OF SERVICE of Plaintiffs' Supplemental Objections and Responses to Defendant's First Set of Interrogatories (Nos. 6 & 8) filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 03/18/2024) (3)
Mar 15, 2024 122 SO ORDERED, re 121 STIPULATION TO EXTEND TIME for the parties to submit a revised proposed scheduling order, pursuant to the Court's March 6, 2024 Minute Entry, to March 22, 2024, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 3/15/2024. (kmd) (Entered: 03/15/2024) (2)
Mar 14, 2024 120 NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendant's Notice of Deposition of Novo Nordisk Inc. and Novo Nordisk A/S Pursuant to Fed. R. Civ. P. 30(b)(6) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 03/14/2024) (3)
Mar 14, 2024 121 STIPULATION TO EXTEND TIME for the parties to submit a revised proposed scheduling order, pursuant to the Court's March 6, 2024 Minute Entry, to March 22, 2024 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 03/14/2024) (2)
Mar 12, 2024 117 NOTICE to Take Deposition of Christine Bjrn Jensen on March 20, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 03/12/2024) (3)
Mar 12, 2024 118 NOTICE to Take Deposition of Eva Horn Mller on March 19, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 03/12/2024) (3)
Mar 12, 2024 119 NOTICE to Take Deposition of Dorthe Kot Engelund on March 15, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 03/12/2024) (3)
Mar 8, 2024 116 REDACTED VERSION of 107 Letter, by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1-5)(Stamoulis, Stamatios) (Entered: 03/08/2024) (0)
Mar 7, 2024 114 [SEALED] Official Transcript of Discovery and Status Conference held on March 6, 2024 before Chief Judge Connolly. Court Reporter/Transcriber Bonnie Archer, Email: Bonnie_Archer@ded.uscourts.gov. Modified on 6/5/2024 (rlr). (Entered: 03/07/2024) (0)
Mar 7, 2024 115 REDACTED VERSION of 101 Letter by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Ex. A, # 2 Ex. B, # 3 Ex. C, # 4 Ex. D, # 5 Ex. E, # 6 Ex. F, # 7 Ex. G)(Murray, Travis) (Entered: 03/07/2024) (0)
Mar 4, 2024 113 SO ORDERED, re 109 Stipulation Extending Certain Deadlines, filed by Novo Nordisk A/S, Novo Nordisk Inc. Resetting Scheduling Order Deadlines: Fact Discovery completed by 4/5/2024. Signed by Judge Colm F. Connolly on 3/4/2024. (kmd) (Entered: 03/04/2024) (2)
Mar 3, 2024 112 Letter to the Honorable Colm F. Connolly from Stamatios Stamoulis regarding March 6, 2024 Status Conference - re 108 Letter. (Stamoulis, Stamatios) (Entered: 03/03/2024) (1)
Mar 1, 2024 106 NOTICE OF SERVICE of (1) Plaintiffs' Objections and Responses to Defendant's Second Set of Requests for Production to Plaintiffs (Nos. 38-44), (2) Plaintiffs' Objections and Responses to Defendant's Second Set of Interrogatories (Nos. 9-11) and (3) Plaintiffs' Objections and Responses to Defendant's First Set of Requests for Admission to Plaintiffs (Nos. 1-6) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 03/01/2024) (3)
Mar 1, 2024 107 [SEALED] Letter to the Honorable Colm F. Connolly from Stamatios Stamoulis regarding Responding to Plaintiff's Dispute Letter - re 101 Letter. (Attachments: # 1 Exhibit 1-5)(Stamoulis, Stamatios) (Main Document 107 replaced on 3/4/2024) (nmf, ). (Entered: 03/01/2024) (0)
Mar 1, 2024 108 Letter to The Honorable Colm F. Connolly from Travis Murray regarding Scheduling - re 102 Letter. (Murray, Travis) (Entered: 03/01/2024) (2)
Mar 1, 2024 109 STIPULATION and [Proposed] Order Extending Certain Deadlines - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 03/01/2024) (2)
Mar 1, 2024 110 NOTICE OF SERVICE of Defendants Objections and Responses to Plaintiffs Second Set of Request for Production of Documents and Things (Nos. 110-119) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 03/01/2024) (2)
Mar 1, 2024 111 NOTICE OF SERVICE of Defendants Supplemental Initial Disclosures Under Fed. R. Civ. P. 26(a)(1) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 03/01/2024) (2)
Feb 29, 2024 105 ORDER granting in part and denying in part 103 MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices. The Motion is granted as to David L. Anstaett, Esq. and Shannon M. Bloodworth, Esq. The Motion is denied as to Preston Imperatore, Esq. Signed by Judge Colm F. Connolly on 2/29/2024. (kmd) (Entered: 02/29/2024) (1)
Feb 28, 2024 101 [SEALED] Letter to The Honorable Colm F. Connolly from Travis Murray regarding Discovery Dispute. (Attachments: # 1 Ex. A, # 2 Ex. B, # 3 Ex. C, # 4 Ex. D, # 5 Ex. E, # 6 Ex. F, # 7 Ex. G)(Murray, Travis) (Entered: 02/28/2024) (0)
Feb 28, 2024 102 Letter to the Honorable Colm F. Connolly from Stamatios Stamoulis regarding Scheduling Issues to be Addressed in Advance of March 6, 2024 Conference - re 101 Letter. (Stamoulis, Stamatios) (Entered: 02/28/2024) (3)
Feb 28, 2024 103 MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 02/28/2024) (3)
Feb 28, 2024 104 MOTION to Compel Discovery re 101 [SEALED] Letter to The Honorable Colm F. Connolly from Travis Murray regarding Discovery Dispute - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Certification Regarding Typeface Requirements, # 2 D. Del. LR 7.1.1 Certification, # 3 Text of Proposed Order)(Murray, Travis) (Entered: 02/28/2024) (0)
Feb 20, 2024 97 NOTICE to Take Deposition of Kuntal Maiti on March 1, 2024 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 02/20/2024) (3)
Feb 20, 2024 98 NOTICE to Take Deposition of Pat Vallano on March 1, 2024 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 02/20/2024) (3)
Feb 20, 2024 99 NOTICE to Take Deposition of Dilip Jayagopal on March 1, 2024 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 02/20/2024) (3)
Feb 20, 2024 100 NOTICE to Take Deposition of Nitin Bhattad on March 1, 2024 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 02/20/2024) (3)
Feb 15, 2024 96 NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Defendant's First Set of Interrogatories (Nos. 1-8) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 02/15/2024) (3)
Feb 2, 2024 95 REDACTED VERSION of 91 Notice to Take Deposition by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 02/02/2024) (15)
Jan 31, 2024 92 NOTICE to Take Deposition of NIKLAS OHRNER on February 27, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/31/2024) (3)
Jan 31, 2024 93 NOTICE OF SERVICE of Second Set of Requests for Production of Documents and Things to Defendant Mylan Pharmaceuticals Inc. (Nos. 110119) filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 01/31/2024) (3)
Jan 31, 2024 94 NOTICE OF SERVICE of (1) Defendants Second Set of Requests for Production to Plaintiffs (Nos. 38-44), (2) Defendants First Set of Requests for Admission to Plaintiffs (Nos. 1-6), and (3) Defendants Second Set of Interrogatories to Plaintiffs (Nos. 9-11) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/31/2024) (2)
Jan 30, 2024 91 [SEALED] NOTICE to Take Deposition of Mylan Pharmaceuticals Inc. on February 23, 2024 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 01/30/2024) (0)
Jan 26, 2024 90 NOTICE to Take Deposition of 30(b)(6) Corporate Representative filed by Mylan Pharmaceuticals Inc., Viatris Inc..(Stamoulis, Stamatios) (Entered: 01/26/2024) (16)
Jan 25, 2024 81 NOTICE to Take Deposition of Andrew Mark Louw on February 22, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/25/2024) (3)
Jan 25, 2024 82 NOTICE to Take Deposition of Joakim Lundqvist on February 27, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/25/2024) (3)
Jan 25, 2024 83 NOTICE to Take Deposition of Sren Snitker on February 16, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/25/2024) (3)
Jan 25, 2024 84 NOTICE to Take Deposition of Michael Duelund Srensen on February 23, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/25/2024) (3)
Jan 25, 2024 85 NOTICE to Take Deposition of Stephanie DeChiaro on February 20, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/25/2024) (3)
Jan 25, 2024 86 NOTICE to Take Deposition of Dorthe Kot Engelund on February 26, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/25/2024) (3)
Jan 25, 2024 87 NOTICE to Take Deposition of Aneil Batra on February 28, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/25/2024) (3)
Jan 25, 2024 88 NOTICE to Take Deposition of Eva Horn Mller on February 21, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/25/2024) (3)
Jan 25, 2024 89 NOTICE to Take Deposition of Christine Bjrn Jensen on February 29, 2024 filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/25/2024) (3)
Jan 16, 2024 80 NOTICE OF SERVICE of Defendants First Set of Interrogatories to Plaintiffs (Nos. 1-8) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 01/16/2024) (2)
Dec 15, 2023 77 Letter to the Honorable Colm F. Connolly from Stamatios Stamoulis regarding Supplemental Argument re Claim Construction. (Stamoulis, Stamatios) (Entered: 12/15/2023) (2)
Dec 15, 2023 78 Letter to The Honorable Colm F. Connolly from Brian P. Egan regarding construction of claim term - re Oral Order,. (Egan, Brian) (Entered: 12/15/2023) (4)
Dec 15, 2023 79 PROPOSED ORDER -- Claim Construction -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 12/15/2023) (3)
Dec 14, 2023 76 Official Transcript of Markman Hearing held on December 13, 2023 before Chief Judge Connolly. Court Reporter/Transcriber Bonnie Archer, Email: Bonnie_Archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/4/2024. Redacted Transcript Deadline set for 1/16/2024. Release of Transcript Restriction set for 3/13/2024. (nmf) (Entered: 12/14/2023) (122)
Dec 12, 2023 74 Letter to The Honorable Colm F. Connolly from Travis Murray regarding response to the Court's Oral Order dated December 11, 2023 - re Oral Order,,,,. (Murray, Travis) (Entered: 12/12/2023) (1)
Dec 12, 2023 75 Letter to the Honorable Colm F. Connolly from Stamatios Stamoulis regarding Responding to Court's Oral Order on Proposed Constructions. (Stamoulis, Stamatios) (Entered: 12/12/2023) (4)
Dec 8, 2023 73 ORDER granting 72 Amended MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices . Signed by Judge Colm F. Connolly on 12/8/2023. (kmd) (Entered: 12/08/2023) (3)
Dec 7, 2023 72 Amended MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 12/07/2023) (3)
Dec 6, 2023 69 MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 12/06/2023) (3)
Dec 6, 2023 70 ORDER granting 69 MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices. Signed by Judge Colm F. Connolly on 12/6/2023. (kmd) (Entered: 12/06/2023) (3)
Dec 6, 2023 71 MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 12/06/2023) (3)
Nov 29, 2023 67 CLAIM Construction Chart by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 11/29/2023) (13)
Nov 29, 2023 68 Letter to The Honorable Colm F. Connolly from Travis Murray regarding Amended Joint Claim Construction Chart - re 67 Claim Construction Chart. (Murray, Travis) (Entered: 11/29/2023) (2)
Nov 20, 2023 66 SO ORDERED, re 65 STIPULATION TO EXTEND TIME to Amend Pleadings to December 22, 2023, filed by Mylan Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 11/20/2023. (kmd) (Entered: 11/20/2023) (2)
Nov 17, 2023 65 STIPULATION TO EXTEND TIME to Amend Pleadings to December 22, 2023 - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 11/17/2023) (2)
Nov 9, 2023 63 JOINT CLAIM CONSTRUCTION BRIEF filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 11/09/2023) (30)
Nov 9, 2023 64 APPENDIX re 63 Joint Claim Construction Brief by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Ex A - US Patent No 9764003, # 2 Ex B - US Patent No 10888605, # 3 Ex C - 003 FH_2014-03-19 Specification, # 4 Ex D - 003 FH_2014-12-19 Preliminary Amendment, # 5 Ex E - 003 FH_2016-03-02 Amendment, # 6 Ex F - 003 FH_2016-08-12 Amendment, # 7 Ex G - 003 FH_2016-09-22 Office Action, # 8 Ex H - 003 FH_2017-03-21 Amendment, # 9 Ex I - 003 FH_2017-04-24 Notice of Allowance, # 10 Ex J - 605 FH_2020-01-28 Application and Claims, # 11 Ex K - 605 FH_2020-05-01 Office Action, # 12 Ex L - 605 FH_2020-07-31 Amendment, # 13 Ex M - 605 FH_11-20-2020_Notice of Allowance, # 14 Ex N - Claim Construction Hrg Tr (excerpted) 22-MD-3038 (DI 146), # 15 Ex O - Claim Construction Order 22-MD-3038 (DI 148), # 16 Ex P - Am Heritage Dictionary, # 17 Ex Q - Stedmans Med Dictionary, # 18 Ex R - Wegovy Prescribing Information)(Murray, Travis) (Entered: 11/09/2023) (0)
Nov 6, 2023 62 NOTICE OF SERVICE of (1) Defendants Objections and Responses to Plaintiffs First Set of Interrogatories (Nos. 1-9) and (2) Defendants Objections and Responses to Plaintiffs First Set of Requests for Production of Documents and Things (Nos. 1-109) filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 11/06/2023) (2)
Nov 2, 2023 61 NOTICE OF SERVICE of Mylan Pharmaceuticals Inc.s Sur-Reply Claim Construction Brief filed by Mylan Pharmaceuticals Inc..(Stamoulis, Stamatios) (Entered: 11/02/2023) (2)
Oct 31, 2023 57 STIPULATION and [Proposed] Order Regarding Compound Patents - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 10/31/2023) (7)
Oct 31, 2023 58 SO ORDERED, re 57 Stipulation Regarding Compound Patents, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 10/31/2023. (kmd) (Entered: 10/31/2023) (7)
Oct 31, 2023 59 STIPULATION of Dismissal and [Proposed] Order as to Defendant Viatris Inc. - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 10/31/2023) (3)
Oct 31, 2023 60 SO ORDERED, re 59 Stipulation of Dismissal as to Defendant Viatris Inc., filed by Novo Nordisk A/S, Novo Nordisk Inc. Party Viatris Inc. terminated. Attorneys Brandon M. White, Bryan D. Beel, and Stamatios Stamoulis terminated. Signed by Judge Colm F. Connolly on 10/31/2023. (kmd) (Entered: 10/31/2023) (3)
Oct 30, 2023 56 NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendants' First Set of Requests for Production (Nos. 1-37) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 10/30/2023) (3)
Oct 12, 2023 55 NOTICE OF SERVICE of Novo Nordisk's Claim Construction Reply Brief filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 10/12/2023) (3)
Oct 5, 2023 54 NOTICE OF SERVICE of (1) Plaintifffs Novo Nordisk Inc. and Novo Noridsk A/Ss First Set of Requests for Production of Documents and Things to Defendants (Nos. 1109) and (2) Plaintifffs Novo Nordisk Inc. and Novo Noridsk A/Ss First Set of Interrogatories to Defendants (Nos. 19) filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 10/05/2023) (3)
Sep 29, 2023 53 MOTION for Pro Hac Vice Appearance of Attorney David L. Anstaett - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 09/29/2023) (4)
Sep 28, 2023 52 NOTICE OF SERVICE of Defendants First Set of Requests for Production to Plaintiffs filed by Mylan Pharmaceuticals Inc., Viatris Inc..(Stamoulis, Stamatios) (Entered: 09/28/2023) (2)
Sep 21, 2023 51 NOTICE OF SERVICE of Viatris Inc. and Mylan Pharmaceuticals Inc.s Answering Claim Construction Brief filed by Mylan Pharmaceuticals Inc., Viatris Inc..(Stamoulis, Stamatios) (Entered: 09/21/2023) (2)
Aug 24, 2023 50 NOTICE OF SERVICE of Novo Nordisk's Opening Claim Construction Brief - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 08/24/2023) (3)
Aug 17, 2023 49 NOTICE OF SERVICE of Novo Nordisk's Disclosure of Final Search Terms Pursuant to Section IV of the ESI Order (D.I. 43) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 08/17/2023) (3)
Aug 11, 2023 48 NOTICE OF SERVICE of Plaintiffs Novo Nordisk A/S and Novo Nordisk Inc.'s Disclosure of ESI Search Terms Pursuant to Section IV of the ESI Order (D.I. 43; D.I. 46) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 08/11/2023) (3)
Aug 10, 2023 46 SO ORDERED, re 45 STIPULATION TO EXTEND TIME for the parties to exchange a list of intended terms to be used to search their ESI (D.I. 43) to August 10, 2023, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 8/10/2023. (kmd) (Entered: 08/10/2023) (2)
Aug 10, 2023 47 NOTICE OF SERVICE of Defendants identification of terms Defendants intends to use to search their ESI filed by Mylan Pharmaceuticals Inc., Viatris Inc..(Stamoulis, Stamatios) (Entered: 08/10/2023) (2)
Aug 9, 2023 45 STIPULATION TO EXTEND TIME for the parties to exchange a list of intended terms to be used to search their ESI (D.I. 43) to August 10, 2023 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 08/09/2023) (2)
Aug 8, 2023 44 NOTICE OF SERVICE of (1) Plaintiffs' Initial Infringement Contentions Regarding Defendants Viatris Inc. and Mylan Pharmaceuticals Inc. and (2) Plaintiffs' Initial Responses to Defendants' Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 9,764,003; 10,888,605; and 11,318,191 - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 08/08/2023) (4)
Aug 3, 2023 42 STIPULATED PROTECTIVE ORDER Pursuant to Federal Rule of Civil Procedure 26(c). Signed by Judge Colm F. Connolly on 8/3/2023. (kmd) (Entered: 08/03/2023) (30)
Aug 3, 2023 43 SO ORDERED, re 41 Stipulated Order Regarding the Discovery of Electronically Stored Information, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 8/3/2023. (kmd) (Entered: 08/03/2023) (15)
Aug 2, 2023 40 PROPOSED ORDER Protective Order by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 08/02/2023) (30)
Aug 2, 2023 41 STIPULATION Stipulated Order Regarding the Discovery of Electronically Stored Information by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 08/02/2023) (15)
Jul 31, 2023 37 CLAIM Construction Chart by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Ex. A - '343 Patent, # 2 Ex. B - '122 Patent, # 3 Ex. C - '003 Patent, # 4 Ex. D - '605 Patent, # 5 Ex. E - '191 Patent)(Egan, Brian) (Entered: 07/31/2023) (0)
Jul 31, 2023 38 MOTION for Claim Construction re 37 Claim Construction Chart, - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 07/31/2023) (3)
Jul 31, 2023 39 MOTION for Claim Construction - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 07/31/2023) (2)
Jul 26, 2023 36 STIPULATION TO EXTEND TIME for Parties to Submit Proposed Protective Order and Proposed ESI Order pursuant to Court's Scheduling Order [D.I. 27] to August 2, 2023 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 07/26/2023) (2)
Jul 21, 2023 34 NOTICE OF SERVICE of Plaintiffs' Proposed Constructions and Supporting Intrinsic Evidence filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) (Entered: 07/21/2023) (3)
Jul 21, 2023 35 NOTICE OF SERVICE of Defendants Identification of Proposed Constructions and Intrinsic Evidence filed by Mylan Pharmaceuticals Inc., Viatris Inc..(Stamoulis, Stamatios) (Entered: 07/21/2023) (2)
Jul 19, 2023 32 STIPULATION TO EXTEND TIME to submit a proposed Protective Order and a proposed ESI Order to July 26, 2023 - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 07/19/2023) (2)
Jul 19, 2023 33 SO ORDERED, re 32 STIPULATION TO EXTEND TIME to submit a proposed Protective Order and a proposed ESI Order to July 26, 2023, filed by Viatris Inc., Mylan Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 7/19/2023. (kmd) (Entered: 07/19/2023) (2)
Jul 11, 2023 31 SO ORDERED, re 30 STIPULATION TO EXTEND TIME to Submit Proposed Protective Order to July 19, 2023, filed by Mylan Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 7/11/2023. (kmd) (Entered: 07/11/2023) (2)
Jul 10, 2023 30 STIPULATION TO EXTEND TIME to Submit Proposed Protective Order to July 19, 2023 - filed by Mylan Pharmaceuticals Inc.. (Stamoulis, Stamatios) (Entered: 07/10/2023) (2)
Jun 28, 2023 29 NOTICE OF SERVICE of Plaintiffs' Identification of Inventors Employed by Plaintiffs and/or Represented by Counsel for Plaintiffs - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) (Entered: 06/28/2023) (3)
Jun 22, 2023 28 NOTICE OF SERVICE of (1) Defendants Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 9,764,003; 10,888,605; and 11,318,191 and (2) Defendants Initial Noninfringement Contentions filed by Mylan Pharmaceuticals Inc., Viatris Inc..(Stamoulis, Stamatios) (Entered: 06/22/2023) (2)
Jun 21, 2023 27 SCHEDULING ORDER: Joinder of Parties due by 11/17/2023. Amended Pleadings due by 11/17/2023. Fact Discovery completed by 3/1/2024. Expert Discovery due by 8/9/2024. Joint Claim Construction Brief due by 11/9/2023. A Markman Hearing is set for 12/13/2023 at 09:00 AM in Courtroom 4B before Judge Colm F. Connolly. Proposed Pretrial Order due by 11/20/2024. A Final Pretrial Conference is set for 12/11/2024 at 03:00 PM in Courtroom 4B before Judge Colm F. Connolly. A Bench Trial is set for 12/16/2024 at 08:30 AM in Courtroom 4B before Judge Colm F. Connolly. Signed by Judge Colm F. Connolly on 6/21/2023. (nmf) (Entered: 06/21/2023) (28)
Jun 20, 2023 26 Joint PROPOSED ORDER -- [Proposed] Scheduling Order -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Cover Letter to The Honorable Colm F. Connolly)(Egan, Brian) (Entered: 06/20/2023) (Main Document) (28)
Jun 20, 2023 26 Joint PROPOSED ORDER -- [Proposed] Scheduling Order -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Cover Letter to The Honorable Colm F. Connolly)(Egan, Brian) (Entered: 06/20/2023) (Cover Letter to The Honorable Colm F. Connolly) (1)
Jun 8, 2023 25 Official Transcript of In-Person Scheduling Conference held on June 6, 2023 before Chief Judge Connolly. Court Reporter/Transcriber Bonnie Archer, Email: Bonnie_Archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 6/29/2023. Redacted Transcript Deadline set for 7/10/2023. Release of Transcript Restriction set for 9/6/2023. (nmf) (Entered: 06/08/2023) (0)
Jun 6, 2023 N/A SO ORDERED, re 24 MOTION for Pro Hac Vice Appearance of Attorney Shannon M. Bloodworth, filed by Viatris Inc., Mylan Pharmaceuticals Inc. Ordered by Judge Colm F. Connolly on 6/6/2023. (kmd) (Entered: 06/06/2023) (0)
Jun 6, 2023 N/A Minute Entry for proceedings held before Judge Colm F. Connolly - In-Person Scheduling Conference held on 6/6/2023. (Court Reporter Bonnie Archer.) Counsel to submit a revised proposed scheduling order to the Court on or before June 20, 2023. (nmf) (Entered: 06/06/2023) (0)
Jun 5, 2023 24 MOTION for Pro Hac Vice Appearance of Attorney Shannon M. Bloodworth - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 06/05/2023) (4)
May 30, 2023 23 MOTION for Pro Hac Vice Appearance of Attorney Philip S. May - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 05/30/2023) (4)
May 30, 2023 N/A SO ORDERED, re 23 MOTION for Pro Hac Vice Appearance of Attorney Philip S. May, filed by Novo Nordisk A/S, Novo Nordisk Inc. Ordered by Judge Colm F. Connolly on 5/30/2023. (kmd) (Entered: 05/30/2023) (0)
May 30, 2023 N/A Pro Hac Vice Attorney Philip S. May for Novo Nordisk A/S and Novo Nordisk Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (apk) (Entered: 05/30/2023) (0)
May 17, 2023 N/A Pro Hac Vice Attorney Bryan D. Beel and Brandon M. White for Mylan Pharmaceuticals Inc. and Viatris Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 05/17/2023) (0)
May 16, 2023 N/A Pro Hac Vice Attorney Emily J. Greb for Mylan Pharmaceuticals Inc., Viatris Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk) (Entered: 05/16/2023) (0)
May 15, 2023 22 NOTICE OF SERVICE of Novo Nordisk's Preliminary Disclosure of Asserted Claims filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) (Entered: 05/15/2023) (3)
May 10, 2023 N/A SO ORDERED, re 21 MOTION for Pro Hac Vice Appearance of Attorney Brandon M. White, Emily J. Greb, and Bryan D. Beel, filed by Viatris Inc., Mylan Pharmaceuticals Inc. Ordered by Judge Colm F. Connolly on 5/10/2023. (kmd) (Entered: 05/10/2023) (0)
May 10, 2023 N/A ORAL ORDER Setting In-Person Scheduling Conference:( A Scheduling Conference is set for 6/6/2023 at 01:30 PM in Courtroom 4B before Judge Colm F. Connolly.) Ordered by Judge Colm F. Connolly on 5/10/2023. (nmf) (Entered: 05/10/2023) (0)
May 9, 2023 21 MOTION for Pro Hac Vice Appearance of Attorney Brandon M. White, Emily J. Greb, and Bryan D. Beel - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 05/09/2023) (6)
May 8, 2023 18 NOTICE OF SERVICE of (1) Disclosures Under Paragraph 3 of the District of Delaware Default Standard; and (2) Initial Disclosures Pursuant to Fed. R. Civ. P. 26(A) filed by Novo Nordisk A/S, Novo Nordisk Inc..(Egan, Brian) (Entered: 05/08/2023) (3)
May 8, 2023 19 Joint PROPOSED ORDER -- [Proposed] Scheduling Order -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 05/08/2023) (30)
May 8, 2023 20 NOTICE OF SERVICE of (1) Defendants Initial Disclosure Under Fed. R. Civ. P. 26(a)(1) and (2) Defendants Disclosures Pursuant to the Delaware Default Standard for Discovery filed by Mylan Pharmaceuticals Inc., Viatris Inc..(Stamoulis, Stamatios) (Entered: 05/08/2023) (2)
May 4, 2023 N/A SO ORDERED, re 17 STIPULATION TO EXTEND TIME to Submit Proposed Scheduling Order to May 8, 2023, filed by Viatris Inc., Mylan Pharmaceuticals Inc. Setting Deadlines: Notice of Compliance deadline set for 5/8/2023. Ordered by Judge Colm F. Connolly on 5/4/2023. (kmd) (Entered: 05/04/2023) (0)
May 3, 2023 17 STIPULATION TO EXTEND TIME to Submit Proposed Scheduling Order to May 8, 2023 - filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 05/03/2023) (2)
Apr 24, 2023 16 SO ORDERED, re 15 STIPULATION TO EXTEND TIME for the parties to submit a proposed scheduling order pursuant to the Court's Order (D.I. 10) to May 3, 2023, filed by Novo Nordisk A/S, Novo Nordisk Inc. ReSet Deadlines: Notice of Compliance deadline set for 5/3/2023. Signed by Judge Colm F. Connolly on 4/24/2023. (kmd) (Entered: 04/24/2023) (2)
Apr 21, 2023 14 ANSWER to 11 Answer to Complaint, Counterclaim -- Plaintiffs' Answer to Counterclaims -- by Novo Nordisk A/S, Novo Nordisk Inc..(Blumenfeld, Jack) (Entered: 04/21/2023) (16)
Apr 21, 2023 15 STIPULATION TO EXTEND TIME for the parties to submit a proposed scheduling order pursuant to the Court's Order (D.I. 10) to May 3, 2023 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Blumenfeld, Jack) (Entered: 04/21/2023) (2)
Apr 17, 2023 N/A SO ORDERED, re 13 STIPULATION TO EXTEND TIME for the parties to submit a proposed scheduling order pursuant to the Court's Order (D.I. 10) to April 24, 2023, filed by Novo Nordisk A/S, Novo Nordisk Inc. Resetting Deadlines: Notice of Compliance deadline set for 4/24/2023. Ordered by Judge Colm F. Connolly on 4/17/2023. (kmd) (Entered: 04/17/2023) (0)
Apr 14, 2023 13 STIPULATION TO EXTEND TIME for the parties to submit a proposed scheduling order pursuant to the Court's Order (D.I. 10) to April 24, 2023 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Blumenfeld, Jack) (Entered: 04/14/2023) (2)
Mar 31, 2023 11 ANSWER to 1 Complaint, , COUNTERCLAIM against All Plaintiffs by Mylan Pharmaceuticals Inc., Viatris Inc..(Stamoulis, Stamatios) (Entered: 03/31/2023) (30)
Mar 31, 2023 12 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Viatris Inc. for Mylan Pharmaceuticals Inc. filed by Mylan Pharmaceuticals Inc., Viatris Inc.. (Stamoulis, Stamatios) (Entered: 03/31/2023) (2)
Mar 14, 2023 10 ORDER, having been assigned these cases which are listed as related to earlier filed cases that are currently proceeding on an agreed upon schedule entered by the Court; IT IS ORDERED that, on or before April 17, 2023, counsel for the parties shall confer regarding coordination of the cases and submit a proposed scheduling order to the Court or otherwise advise the Court that a separate scheduling conference is needed.ORDER, Setting Deadlines: ( Notice of Compliance deadline set for 4/17/2023.) Signed by Judge Colm F. Connolly on 3/14/2023. Associated Cases: 1:23-cv-00101-CFC, 1:23-cv-00179-CFC(nmf) (Entered: 03/14/2023) (2)
Feb 23, 2023 N/A Pro Hac Vice Attorney Scott Miller, Joshua Reich, Naz Erdeniz Wehrli, Daniel J. Klein, Peter Sandel, Jenny C. Wu, Josephine Young, and Nicholas P. Groombridge for Novo Nordisk A/S and Novo Nordisk Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 02/23/2023) (0)
Feb 21, 2023 N/A SO ORDERED, re 9 MOTION for Pro Hac Vice Appearance of Attorney Nicholas P. Groombridge, Josephine Young, Jenny C. Wu, Peter Sandel, Daniel J. Klein, Naz E. Wehrli, Joshua Reich and Scott Mille,r filed by Novo Nordisk A/S, Novo Nordisk Inc. Ordered by Judge Colm F. Connolly on 2/21/2023. (kmd) (Entered: 02/21/2023) (0)
Feb 17, 2023 9 MOTION for Pro Hac Vice Appearance of Attorney Nicholas P. Groombridge, Josephine Young, Jenny C. Wu, Peter Sandel, Daniel J. Klein, Naz E. Wehrli, Joshua Reich and Scott Miller - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 02/17/2023) (10)
Feb 8, 2023 8 WAIVER OF SERVICE returned executed by Novo Nordisk Inc., Novo Nordisk A/S: For Mylan Pharmaceuticals Inc. waiver sent on 1/30/2023, answer due 3/31/2023; Viatris Inc. waiver sent on 1/30/2023, answer due 3/31/2023. (Egan, Brian) (Entered: 02/08/2023) (1)
Feb 1, 2023 N/A Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) (Entered: 02/01/2023) (0)
Feb 1, 2023 7 STANDING ORDER REGARDING BRIEFING IN ALL CASES (nmf) (Entered: 02/01/2023) (2)
Jan 27, 2023 1 COMPLAINT FOR ANDA/PATENT INFRINGEMENT filed against Mylan Pharmaceuticals Inc., Viatris Inc. ( Filing fee $ 402, receipt number ADEDC-4054183.) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # 1 Exhibit 1-5, # 2 Civil Cover Sheet) (vfm) (Entered: 01/27/2023) (Main Document) (30)
Jan 27, 2023 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (vfm) (Entered: 01/27/2023) (3)
Jan 27, 2023 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 12/17/2022. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 6/17/2025. (vfm) (Entered: 01/27/2023) (1)
Jan 27, 2023 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,129,343 B2 ;8,536,122 B2 ;9,764,003 B2 ;10,888,605 B2 ;11,318,191 B2. (vfm) (Entered: 01/27/2023) (1)
Jan 27, 2023 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novo Nordisk US Holdings Inc., Corporate Parent NNAS, Corporate Parent Novo Nordisk Commercial Holdings, Inc. for Novo Nordisk Inc.; Corporate Parent Novo Holdings A/S, Corporate Parent Novo Nordisk Foundation for Novo Nordisk A/S filed by Novo Nordisk A/S, Novo Nordisk Inc.. (vfm) (Entered: 01/27/2023) (2)
Jan 27, 2023 6 Summons Issued as to Mylan Pharmaceuticals Inc. on 1/27/2023; Viatris Inc. on 1/27/2023. (Attachments: # 1 Summons Issued) (vfm) (Entered: 01/27/2023) (Main Document) (2)
Jan 27, 2023 N/A Remark: MDL Panel Notified. (vfm) (Entered: 01/27/2023) (0)
Jan 27, 2023 1 COMPLAINT FOR ANDA/PATENT INFRINGEMENT filed against Mylan Pharmaceuticals Inc., Viatris Inc. ( Filing fee $ 402, receipt number ADEDC-4054183.) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # 1 Exhibit 1-5, # 2 Civil Cover Sheet) (vfm) (Entered: 01/27/2023) (Exhibit 1-5) (30)
Jan 27, 2023 1 COMPLAINT FOR ANDA/PATENT INFRINGEMENT filed against Mylan Pharmaceuticals Inc., Viatris Inc. ( Filing fee $ 402, receipt number ADEDC-4054183.) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # 1 Exhibit 1-5, # 2 Civil Cover Sheet) (vfm) (Entered: 01/27/2023) (Civil Cover Sheet) (2)
Jan 27, 2023 6 Summons Issued as to Mylan Pharmaceuticals Inc. on 1/27/2023; Viatris Inc. on 1/27/2023. (Attachments: # 1 Summons Issued) (vfm) (Entered: 01/27/2023) (Summons Issued) (2)
Menu